Posible encefalopatía tóxica no alcohólica por vacuna Covid en paciente con hepatopatía

Possible non-alcoholic toxic encephalopathy due to Covid vaccine in a patient with liver disease

  • José María González San José Centro de Salud de Herencia, Servicio de Salud de Castilla la Mancha (SESCAM) (Ciudad Real, España)
Palabras clave: Vacuna Covid, Nanopartículas Lipídicas (LNP), Encefalopatía, Hepatopatía, Barrera Hematoencefálica (BBB)
Key-words: Covid vaccine, Lipid Nanoparticles (LNP), Encephalopathy, Liver disease, Blood-brain barrier (BBB)

Resumen

Abstract

Bibliografía

1. Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs. 2019. 79(Suppl 1), 5–9. https://doi.org/10.1007/s40265-018-1018-z
2. Medline Plus. National Library of Medicine (NIH – NLM) U.S. Department of Health and Human Services. ADAM Health Solutions. 1997-2022. Encefalopatía Hepática. (Sitio Web). https://medlineplus.gov/spanish/ency/article/000302.htm.
3. Bosch B, van der Zee R, de Haan C, & Rottier P. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. Journal of Virology 2003; 77(16). https://doi.org/10.1128/jvi.77.16.8801-8811.2003
4. González San José, José María. Necrosis de pie por isquemia arterial aguda tras vacuna Covid. Evidentia. 2022; 29: e13916. http://ciberindex.com/c/ev/e13916
5. Romero de San Pío, E., Romero de San Pío, M., & González Sánchez, S. Derecho al honor, al prestigio y a la salvaguarda de la dignidad profesional en enfermería. Revista Ene De Enfermería. 2016; 10(1). http://ene-enfermeria.org/ojs/index.php/ENE/article/view/607
6. Organización Mundial de la Salud. Centro Internacional de monitorización de medicamentos. Centro de monitorización de Uppsala. Datos de Efectos Adversos para “Covid-19 vaccine”. (VIGIACCESS) https://www.vigiaccess.org/
7. Perez, Jean Claude, Moret-Chalmin, Claude, Montagnier, L. Towards the emergence of a new form of the neurodegenerative Creutzfeldt-Jakob disease: Twenty-six cases of CJD declared a few days after a COVID-19 “vaccine” Jab. 2021. Disponible en: https://canadahealthalliance.org/wp-content/uploads/2022/06/V2CJDPerezMoretMontagnierRIP2022REFERENCEARTICLE.pdf
8. National Vaccine Information Center. Creutzfeldt-Jakob disease. MedAlert.org (Sitio Web). 2022. https://medalerts.org/vaersdb/findfield.php?TABLE=ON&GROUP1=AGE&EVENTS=ON&SYMPTOMS=Creutzfeldt-Jakob+disease+%2810011384%29&VAX=COVID19
9. Lazarus R, Klompas M, & Berstein S. Electronic Support for Public Health–Vaccine Adverse Event Reporting System (ESP: VAERS). U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality (AHRQ). 2010 (Rockvi-lle - EEUU). https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf
10. Vaccine Adverse Event Reporting System. (VAERS, Ed.). OPENVAERS. https://openvaers.com/
11. European Mortality Monitoring activity. (EUROMOMO). https://www.euromomo.eu/
12. Desfargues, S., Ciuffi, A. & Witzany, G. Viral Integration and Consequences on Host Gene Expression. Viruses: Essential Agents of Life. 2012; 147-175. https://doi.org/10.1007/978-94-007-4899-6_7
13. Zhang, L., Richards, A., Barrasa, M., Hughes, S., Young, R., & Jaenisch, R. Reverse-transcribed SARS-CoV-2 RNA can inte-grate into the genome of cultured human cells and can be expressed in patient-derived tissues. PNAS. 2021; 118(21). https://doi.org/10.1073/pnas.2105968118
14. Pastrian-Soto G. Presencia y Expresión del Receptor ACE2 (Target de SARS-CoV-2) en Tejidos Humanos y Cavidad Oral. Posibles Rutas de Infección en Órganos Orales. International journal of odontostomatology 2020; 14(4). http://dx.doi.org/10.4067/S0718-381X2020000400501
15. Sun S.-H, Chen Q, Gu H-J, Yang G, Wang Y-X, Huang X-Y et al. A Mouse Model of SARS-CoV-2 Infection and Pathogene-sis. Cell Host & Microbe 2020; 28(1), 124-133. https://doi.org/10.1016/j.chom.2020.05.020
16. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J-C, Turner A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circula-tion Research 2020; 126(10), 1456-1474. https://doi.org/10.1161/CIRCRESAHA.120.317015
17. Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infectious Disease of Poverty 2020; 9(1), 45. https://doi.org/10.1186/s40249-020-00662-x
18. ECHELON Bioscience. Lipid Nanoparticles for RNA Delivery. Disponible en https://www.echelon-inc.com/lipid-nanoparticles-for-rna-delivery/
19. National Center for Biotechnology Information (NCBI). National Institute of Health (NIH). PUBCHEM., SM-102. de Na-tional Center for Biotechnology Information (NCBI): Disponible en https://www.ncbi.nlm.nih.gov/pcsubstance/?term=sm-102
20. National Center for Biotechnology Information (NCBI). National Institute of Health (NIH). PUBCHEM., ALC-0315. de Na-tional Center for Biotechnology Information (NCBI): Disponible en https://www.ncbi.nlm.nih.gov/pcsubstance/?term=alc-0315
21. National Center for Biotechnology Information (NCBI). National Institute of Health (NIH). PUBCHEM., ALC-0159. de Na-tional Center for Biotechnology Information (NCBI): Disponible en https://www.ncbi.nlm.nih.gov/pcsubstance/?term=alc-0159
22. Wang, Y.-J., Wang, J., Hao, D.-L., Yue, Q.-X., Xie, R., De, G.-J., . . . Chen, Y.-J. Preparation of docetaxel-loaded nanomicelles and their anti-Lewis lung cancer effect in vitro. Zhongguo Zhong Yao Za Zhi. 2019. 44(11), 2251-2259. https://doi.org/10.19540/j.cnki.cjcmm.20190326.305
23. Sharpe, M., Easthope, S., Keating, G., & Lamb, H. Polyethylene glycol-liposomal doxorubicin: a review of its use in the man-agement of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 2002; 62(14), 2089-126. https://doi.org/10.2165/00003495-200262140-00012
24. Lim, W., Rajinikanth, P., Mallikarjun, C., & Kang, Y. Formulation and delivery of itraconazole to the brain using a nanolipid carrier system. Int J Nanomedicine 2014; 9, 2117-2126. https://doi.org/10.2147/IJN.S57565
25. Radice, A., Fassio, F., Meucci, E., Iorno, M., & Maccia, D. Potential culprits for immediate hypersensitivity reactions to BNT162b2 mRNA COVID-19 vaccine: not just PEG. (A. A. Ospedalieri, Ed.) Eur Ann Allergy Clin Immunol 2021; 53(5), 240-242. https://doi.org/10.23822/EurAnnACI.1764-1489.214
26. Caballero, M., & Quirce, S. Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Cur-rently Authorized COVID-19 Vaccines. J Investig Allergol Clin Immunol 2021; 31(1), 92-93. https://doi.org/10.18176/jiaci.0667
27. Rojas-Pérez-Ezquerra, P., Crespo Quirós, J., Tornero Molina, P., Baeza Ochoa de Ocáriz, M., & Zubeldia Ortuño, J. Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic Patients. J Investig Allergol Clin Immunol 2021; 31(2), 180-181. https://doi.org/10.18176/jiaci.0683
28. Pall ML. Explaining “Unexplained Illneses”. New York: Informa Healthcare; (Pag 49-68). 2009.
29. Paredes Rizo Mª Luisa. Sensibilidad Química Múltiple: análisis de un caso registrado en un Hospital de referencia. Med. segur. trab. 2018; 64 (251): 217-240. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0465-546X2018000200217&lng=es
30. Glassford JAG. The Neuroinflammatory Etiopathology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Front Physiol. 2017; 8(88). https://doi.org/10.3389/fphys.2017.00088

Novedades
Estadísticas
Cómo citar
1.
González San José, José María. Posible encefalopatía tóxica no alcohólica por vacuna Covid en paciente con hepatopatía. Evidentia. 2023; 20: e14291. Disponible en: https://ciberindex.com/c/ev/e14291 [acceso: 23/02/2024]
Sección
Casos Clínicos
Comentarios

DEJA TU COMENTARIO     VER 0 COMENTARIOS

Normas y uso de comentarios


Hay un total de 0 comentarios


INTRODUCIR NUEVO COMENTARIO

Para enviar un comentario, rellene los campos situados debajo. Recuerde que es obligatorio indicar un nombre y un email para enviar su comentario (el email no sera visible en el comentario).

Nombre:
e-mail:
Comentario: